BioStock: BioInvent soon has five drug candidates in six clinical studies

BioInvent has made several advances in the second quarter of 2023, in particular with its lead drug candidate BI-1206. In addition to a strengthened pipeline, the company’s Q2 report highlights progress across the broad portfolio of drug candidates in clinical development. In the report, CEO Martin Welschof reminds that BioInvent will soon have five drug candidates in six parallel patient studies.

Read the article at biostock.se:

https://www.biostock.se/en/2023/09/bioinvent-soon-has-five-drug-candidates-in-six-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/